Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Simon F. Lacey, PhD, Pamela A Shaw, PhD, David T Teachey, MD, Scott L. Weiss, MD, Fang Chen, PhD, Vanessa E Gonzalez, M.B.A, Noelle Frey, MD MS, David L Porter, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Edward Pequignot, M.S., Carl H June, MD, Jan J. Melenhorst, PhD

Blood (2016) 128 (22): 2812.

https://doi.org/10.1182/blood.V128.22.2812.2812

Published: 2016

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Nicole Winchell, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Simon F. Lacey, PhD, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2016) 128 (22): 1100.

https://doi.org/10.1182/blood.V128.22.1100.1100

Published: 2016

Journal Articles

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Karen Thudium Mueller, PharmD, MS, Abhijit Chakraborty, PhD, Patricia A Wood, MD PhD, Rakesh Awasthi, BPharm, Alfonso Quintas-Cardama, MD, Xia Han, MS, Shannon L Maude, MD PhD, Stephan A. Grupp, MD PhD, David L Porter, MD, Noelle Frey, MD MS, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Jan J. Melenhorst, PhD, Carl H June, MD, Simon F. Lacey, PhD

Blood (2016) 128 (22): 220.

https://doi.org/10.1182/blood.V128.22.220.220

Published: 2016

Journal Articles

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Susan R. Rheingold, MD, Lanyi Nora Chen, BS, Shannon L Maude, MD PhD, Richard Aplenc, MD PhD, Christine Barker, BS, David M. Barrett, MD PhD, Colleen Callahan, MSN, Katherine Cebry, Irina Kulikovskaya, PhD, Simon F. Lacey, PhD BS, Bruce L. Levine, PhD, Jan J. Melenhorst, PhD, Pamela A Shaw, PhD, Anna Sparrow, David T Teachey, MD, Mark Duckworth, BS, Carl H. June, MD, Stephan A. Grupp, MD PhD

Blood (2015) 126 (23): 3769.

https://doi.org/10.1182/blood.V126.23.3769.3769

Published: 2015

Journal Articles

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Blood (2015) 126 (23): 683.

https://doi.org/10.1182/blood.V126.23.683.683

Published: 2015

Journal Articles

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Elise A. Chong, MD, Daniel J. Landsburg, MD, Anthony R. Mato, MD MSCE, Simon F. Lacey, PhD BS, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Gaurav D. Shah, MD, Mariusz A. Wasik, MD, Katherine T. Marcucci, PhD, Zhaohui Zheng, MS, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2015) 126 (23): 183.

https://doi.org/10.1182/blood.V126.23.183.183

Published: 2015

Journal Articles

Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells

Paul A. Castillo, MD, Jan J Melenhorst, PhD, Patrick J Hanley, PhD, Michael Keller, MD, Robert A. Krance, MD, Judith Margolin, MD, Ann Leen, PhD, Helen E. Heslop, MD, John Barrett, MD, Cliona M Rooney, PhD, Catherine M. Bollard, MD FRACP, FRCPA

Blood (2014) 124 (21): 2439.

https://doi.org/10.1182/blood.V124.21.2439.2439

Published: 2014

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 966.

https://doi.org/10.1182/blood.V124.21.966.966

Published: 2014

Journal Articles

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Vijay Bhoj, MD PhD, Michael C Milone, MD PhD, Carl H. June, MD, David Porter, MD, Stephan A. Grupp, MD PhD, Jan J Melenhorst, PhD, Simon F. Lacey, PhD BSc, Colleen Callahan, MSN, CRNP, James Capobianchi, Gerald Wertheim, MDPhD, Yolanda Mahnke, PhD

Blood (2014) 124 (21): 1110.

https://doi.org/10.1182/blood.V124.21.1110.1110

Published: 2014

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

Journal Articles

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

Noelle V. Frey, MDMS, Bruce L. Levine, PhD, Simon F. Lacey, PhD BSc, Stephan A. Grupp, MD PhD, Shannon L Maude, MD PhD, Stephen J. Schuster, MD, Pamela Shaw, PhD, Wei-Ting Hwang, PhD, Mariusz A. Wasik, MD, Amrom Obstfeld, MD, Mimi Leung, MPH, Angela Shen, MD, Solveig G. Ericson, MD PhD, Jan J Melenhorst, PhD, Carl H. June, MD, David Porter, MD

Blood (2014) 124 (21): 2296.

https://doi.org/10.1182/blood.V124.21.2296.2296

Published: 2014

Journal Articles

The Spectrum of Human T Cell Receptor (TCR)-Vβ Frequencies Are Established Prior to Thymic Selection.

Jan J. Melenhorst, PhD, Dean Follmann, PhD, Hiroshi Fujiwara, MD, PhD, Austin J. Barrett, MD

Blood (2004) 104 (11): 3240.

https://doi.org/10.1182/blood.V104.11.3240.3240

Published: 2004

NARROW

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Graft Versus Leukemia Response without Graft Versus Host Disease Elicited By Adoptively Transferred Multivirus-Specific T-Cells

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells

The Spectrum of Human T Cell Receptor (TCR)-Vβ Frequencies Are Established Prior to Thymic Selection.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only